ArticleNeuroradiology2026
Core-based voxel-wise T2-FLAIR mismatch analysis for differentiation of IDH-mutant astrocytomas from oligodendrogliomas.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to develop a voxel-wise quantitative framework for the T2-FLAIR mismatch signal in routine MRI scans to differentiate IDH-mutant astrocytomas from oligodendrogliomas.
methodsThis retrospective study analyzed 43 patients with confirmed diffuse gliomas (25 astrocytomas and 18 oligodendrogliomas) using preoperative T2-weighted and FLAIR MRI. A voxel-wise log-ratio mismatch map was created, and whole-tumor regions of interest (ROIs) were defined through manual segmentations and inward tumor boundary restrictions. Five mismatch biomarkers were extracted: PositiveMismatchRatio, MeanMismatchStrength, MismatchStd, PositiveMismatchMean, and LargestMismatchClusterRatio. Group comparisons utilized the Mann-Whitney U test, and diagnostic performance was assessed through receiver operating characteristic (ROC) analysis.
resultsThe analysis revealed that several voxel-wise mismatch biomarkers presented significantly higher values in astrocytomas compared to oligodendrogliomas, particularly in core-restricted ROIs. The best overall performance was achieved by LargestMismatchClusterRatio in the 3-mm core ROI (AUC, 0.786; 95% CI, 0.640-0.914), followed closely by PositiveMismatchRatio in the same ROI (AUC, 0.779; 95% CI, 0.631-0.910). Threshold-based analysis showed that PositiveMismatchRatio in the 3-mm core ROI provided the strongest rule-in performance, with 60.0% sensitivity, 94.4% specificity, a positive likelihood ratio of 10.80, and a diagnostic odds ratio of 25.5. Overall, core restriction improved discrimination performance compared to whole-tumor assessments.
conclusionsCore-based voxel-wise quantification of T2-FLAIR signal discordance showed preliminary diagnostic value for differentiating IDH-mutant astrocytomas from oligodendrogliomas, particularly as a high-specificity rule-in approach. External validation in larger multicenter cohorts is required before clinical application.
Indexed as
Identifiers
42384075What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.